Patent: 7,291,605
✉ Email this page to a colleague
Summary for Patent: 7,291,605
| Title: | Methods of treating various cancers using melanoma differentiation associated protein-7 |
| Abstract: | This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a method for reversing the cancerous phenotype of a cancer cell by introducing the gene product of the above-described gene into the cancerous cell so as to thereby reverse the cancerous phenotype of the cell. This invention also provides a pharmaceutical composition having the melanoma differentiation associated gene (mda-7) or the gene product of the melanoma differentiation associated gene (mda-7) effective to reverse the cancerous phenotype of a cancer cell and a pharmaceutically acceptable carrier. |
| Inventor(s): | Paul B Fisher |
| Assignee: | Columbia University in the City of New York |
| Application Number: | US11/048,543 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,291,605
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | April 15, 2014 | 7,291,605 | 2025-01-31 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
